TScan stock rises ~15% on FDA nod to start trials of cancer drugs

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

TScan Therapeutics (NASDAQ:TCRX) said that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) applications seeking to start trials of cancer drugs T-Plex, TSC-204-A0201, and TSC-204-C0702.

T-Plex will serve as

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!